Brainsway
Sector: Healthcare & Life Sciences
About Brainsway
Advanced noninvasive neurostimulation treatments for mental health disorders. Proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction. NASDAQ:BWAY and TASE.
Products
Deep TMS System; H-Coil Technology; TMS for Depression/OCD/Smoking
BrainsWay’s treatment platform is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. Deep TMS treatment features unique, patented coils that are fitted into a helmet, which is secured snugly to the patient’s head during the treatment. BrainsWay’s therapy has been utilized in over 60 clinical trials worldwide. In the U.S., the company’s device has been FDA cleared for the treatment of Major Depressive Disorder (MDD) since 2013, FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD) since 2018, FDA cleared as an aid for short-term Smoking Cessation since 2020, and has now received an expanded indication for Anxious Depression.